Compare Stocks: CDNA, IONS, ABVX, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$114.04 +2.7%	$125.75	$69.81 ▼ $148.83	$9.69B	0.96	871,022 shs	1.11 million shs
CDNA CareDx	$49.86 +0.5%	$40.28	$12.37 ▼ $53.67	$2.57B	2.43	1.08 million shs	636,736 shs
IONS Ionis Pharmaceuticals	$58.13 -5.2%	$61.71	$50.01 ▼ $86.74	$10.19B	0.42	2.16 million shs	4.34 million shs
KYMR Kymera Therapeutics	$117.28 -1.1%	$113.97	$40.70 ▼ $130.05	$9.86B	1.96	706,128 shs	591,600 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-2.28%	-4.67%	-10.98%	+5.86%	+35.48%
CDNA CareDx	+1.29%	-2.67%	+3.66%	+114.53%	+258.12%
IONS Ionis Pharmaceuticals	+2.42%	-3.20%	+12.55%	-18.37%	+6.68%
KYMR Kymera Therapeutics	-0.35%	-5.51%	+18.26%	+59.00%	+191.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$114.04 +2.7%	$125.75	$69.81 ▼ $148.83	$9.69B	0.96	871,022 shs	1.11 million shs
CDNA CareDx	$49.86 +0.5%	$40.28	$12.37 ▼ $53.67	$2.57B	2.43	1.08 million shs	636,736 shs
IONS Ionis Pharmaceuticals	$58.13 -5.2%	$61.71	$50.01 ▼ $86.74	$10.19B	0.42	2.16 million shs	4.34 million shs
KYMR Kymera Therapeutics	$117.28 -1.1%	$113.97	$40.70 ▼ $130.05	$9.86B	1.96	706,128 shs	591,600 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	-2.28%	-4.67%	-10.98%	+5.86%	+35.48%
CDNA CareDx	+1.29%	-2.67%	+3.66%	+114.53%	+258.12%
IONS Ionis Pharmaceuticals	+2.42%	-3.20%	+12.55%	-18.37%	+6.68%
KYMR Kymera Therapeutics	-0.35%	-5.51%	+18.26%	+59.00%	+191.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	37.23% Upside
CDNA CareDx	2.63	Moderate Buy	$51.20	2.69% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$94.15	61.96% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$128.70	9.73% Upside

Current Analyst Ratings Breakdown

Latest CDNA, IONS, ABVX, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00
8/31/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Market Perform	$60.00
8/18/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/6/2026	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$135.00
8/6/2026	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
CDNA CareDx	$379.80M	6.79	$0.01 per share	7,615.07	$8.23 per share	6.06
IONS Ionis Pharmaceuticals	$944M	10.23	N/A	N/A	$2.65 per share	21.94
KYMR Kymera Therapeutics	$39.21M	248.71	N/A	N/A	$18.15 per share	6.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	24.09	79.14	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)

Latest CDNA, IONS, ABVX, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9585	N/A	N/A	N/A	$0.78 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.08	-$0.69	+$0.39	-$0.69	$189.10 million	$267.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
CDNA CareDx	N/A	4.58	4.51
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
KYMR Kymera Therapeutics	N/A	10.34	10.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
CDNA CareDx	N/A
IONS Ionis Pharmaceuticals	93.86%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
CDNA CareDx	2.40%
IONS Ionis Pharmaceuticals	1.81%
KYMR Kymera Therapeutics	15.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable

CDNA, IONS, ABVX, and KYMR Headlines

Recent News About These Companies

Can KT-621 Mark a Turning Point for Kymera Therapeutics?

September 3 at 12:50 PM | zacks.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR

September 3 at 4:57 AM | marketbeat.com

Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR

September 3 at 4:39 AM | marketbeat.com

21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC

September 3 at 3:44 AM | marketbeat.com

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

September 2 at 4:01 PM | globenewswire.com

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

September 2 at 3:05 PM | finance.yahoo.com

Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR

September 2 at 4:41 AM | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says

September 2 at 1:18 AM | americanbankingnews.com

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology ...

September 1 at 8:32 AM | finance.yahoo.com

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

September 1 at 7:00 AM | globenewswire.com

Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim

August 31 at 9:05 AM | marketbeat.com

Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR

August 31 at 6:31 AM | marketbeat.com

215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp

August 31 at 3:12 AM | marketbeat.com

Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P.

August 31 at 3:04 AM | marketbeat.com

Wellington Management Group LLP Trims Holdings in Kymera Therapeutics, Inc. $KYMR

August 30, 2026 | marketbeat.com

119,503 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by The Manufacturers Life Insurance Company

August 29, 2026 | marketbeat.com

Freestone Grove Partners LP Purchases New Shares in Kymera Therapeutics, Inc. $KYMR

August 29, 2026 | marketbeat.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock

August 29, 2026 | americanbankingnews.com

20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY

August 28, 2026 | marketbeat.com

Wells Fargo & Company Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

August 27, 2026 | marketbeat.com

Proficio Capital Partners LLC Invests $1.27 Million in Kymera Therapeutics, Inc. $KYMR

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CDNA, IONS, ABVX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

$114.04 +2.96 (+2.66%)

As of 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

CareDx NASDAQ:CDNA

$49.86 +0.26 (+0.52%)

As of 04:00 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Ionis Pharmaceuticals NASDAQ:IONS

$58.13 -3.20 (-5.22%)

As of 04:00 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Kymera Therapeutics NASDAQ:KYMR

$117.28 -1.35 (-1.14%)

As of 04:00 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDNA, IONS, ABVX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDNA, IONS, ABVX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDNA, IONS, ABVX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CDNA, IONS, ABVX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

CareDx NASDAQ:CDNA

Ionis Pharmaceuticals NASDAQ:IONS

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDNA, IONS, ABVX, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDNA, IONS, ABVX, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDNA, IONS, ABVX, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CDNA, IONS, ABVX, and KYMR Company Descriptions

Abivax NASDAQ:ABVX

CareDx NASDAQ:CDNA

Ionis Pharmaceuticals NASDAQ:IONS

Kymera Therapeutics NASDAQ:KYMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools